Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

PURPOSE Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-
AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients …

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy
for relapsed/refractory FLT3-mutated (FLT3 mut) acute myeloid leukemia (AML) but seldom …

Background Patients with relapsed or refractory acute myeloid leukemia (AML) with
mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to …

Background Venetoclax combined with hypomethylating agents is a new standard of care
for newly diagnosed patients with acute myeloid leukaemia (AML) who are 75 years or …

Background Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to
10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted …

For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-
ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of …

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in∼ 12% of patients with
acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2 …